Cardiovascular diseases such as coronary artery disease, cardiomyopathy, stroke, peripheral artery disease, and abdominal/thoracic aortic aneurysm are the number 1 killer worldwide. There are fewer innovative cardiovascular medicines available than there are for oncology. The exciting and encouraging is that ...
Cardiovascular diseases such as coronary artery disease, cardiomyopathy, stroke, peripheral artery disease, and abdominal/thoracic aortic aneurysm are the number 1 killer worldwide. There are fewer innovative cardiovascular medicines available than there are for oncology. The exciting and encouraging is that in April 2022, the U.S. Food and Drug Administration (FDA) approved CamzyosTM (mavacamten) for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM). Considering the limitations and challenges facing the development of novel biologics and small-molecule drugs, many valuable suggestions and new animal models have been proposed.
The cutting-edge discoveries of COVID and anti-cancer agents have provided new opportunities for cardiovascular drug discoveries. Based on these exciting developments, we would like to launch a new special topic “2023 Novel Cardiovascular Drug Development” as a welcome platform for discussion among investigators involved in cardiovascular pharmacology and drug development.
Keywords:
Drug development, Cardiovascular disease, Pharmacology, Novel biologics
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.